Literature DB >> 21219185

Natural innate and adaptive immunity to cancer.

Matthew D Vesely1, Michael H Kershaw, Robert D Schreiber, Mark J Smyth.   

Abstract

The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against cancer. Recently, data obtained from numerous investigations in mouse models of cancer and in humans with cancer offer compelling evidence that particular innate and adaptive immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor-suppressor mechanisms. However, the immune system can also promote tumor progression. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. In this review, we discuss the current experimental and human clinical data supporting a cancer immunoediting process that provide the fundamental basis for further study of immunity to cancer and for the rational design of immunotherapies against cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21219185     DOI: 10.1146/annurev-immunol-031210-101324

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  752 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 2.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 3.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

4.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 5.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

6.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

7.  CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b+ T cell lymphoma.

Authors:  Sreya Bagchi; Sha Li; Chyung-Ru Wang
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110

8.  PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Authors:  Franziska Erlmeier; Arndt Hartmann; Michael Autenrieth; Max Wiedemann; Philipp Ivanyi; Sandra Steffens; Wilko Weichert
Journal:  Med Oncol       Date:  2016-09-30       Impact factor: 3.064

Review 9.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

10.  Association between allergies and risk of pancreatic cancer.

Authors:  Michelle Cotterchio; Elizabeth Lowcock; Thomas J Hudson; Celia Greenwood; Steven Gallinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-19       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.